Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.
Nordicus Partners (OTCQB:NORD) subsidiary Orocidin announced positive preclinical results for its lead periodontitis candidate QR-01 on Oct 22, 2025. The announcement reports a second efficacy signal across two animal models (dog and rat) with a rat study run by the ETEP Research Group at the University Complutense of Madrid.
The rat study had two phases: Phase 1 – 3 weeks (periodontitis induction by ligature + bacterial rinses) and Phase 2 – 7 days (periodontal therapy). Four groups were evaluated: negative control, positive control, placebo with periodontal treatment, and QR-01 with periodontal treatment. Key readouts (probing depth, gingival index, bleeding on probing, plaque index) showed statistically significant differences versus negative control, and bleeding on probing decreased in the QR-01 treatment group while it increased in the placebo group.
Nordicus Partners (OTCQB:NORD) subsidiary Orocidin ha annunciato risultati preclinici positivi per il suo candidato principale per la parodontite QR-01 il 22 ottobre 2025. L'annuncio riporta un secondo segnale di efficacia su due modelli animali (cane e ratto) con uno studio sui ratti condotto dal ETEP Research Group dell'Università Complutense di Madrid.
Lo studio sui ratti ha due fasi: Fase 1 – 3 settimane (induzione della parodontite tramite ligatura e risciacqui batterici) e Fase 2 – 7 giorni (terapia parodontale). Sono stati valutati quattro gruppi: controllo negativo, controllo positivo, placebo con trattamento parodontale e QR-01 con trattamento parodontale. I parametri principali (profondità di sondaggio, indice gengivale, sanguinamento al sondaggio, indice di placca) hanno mostrato differenze statisticamente significative rispetto al controllo negativo, e il sanguinamento al sondaggio è diminuito nel gruppo di trattamento QR-01 mentre è aumentato nel gruppo placebo.
Nordicus Partners (OTCQB:NORD) la subsidiaria Orocidin anunció resultados preclínicos positivos para su candidato líder en periodontitis QR-01 el 22 de octubre de 2025. El anuncio reporta una segunda señal de eficacia en dos modelos animales (perro y rata) con un estudio en ratas realizado por el ETEP Research Group de la Universidad Complutense de Madrid.
El estudio en ratas tuvo dos fases: Fase 1 – 3 semanas (inducción de periodontitis por ligadura y enjuagues bacterianos) y Fase 2 – 7 días (tratamiento periodontal). Se evaluaron cuatro grupos: control negativo, control positivo, placebo con tratamiento periodontal y QR-01 con tratamiento periodontal. Los principales indicadores (profundidad de sondeo, índice gingival, sangrado al sondeo, índice de placa) mostraron diferencias estadísticamente significativas frente al control negativo, y el sangrado al sondeo disminuyó en el grupo de tratamiento QR-01 mientras aumentó en el grupo placebo.
Nordicus Partners (OTCQB:NORD)의 자회사 Orocidin은 QR-01라는 주요 치주염 후보물질에 대한 긍정적인 전임상 결과를 2025년 10월 22일 발표했습니다. 발표 내용은 두 가지 동물모형(개와 쥐)에서의 두 번째 효능 신호를 보고하며, 쥐 연구는 마드리드 컴플루텐세 대학교의 ETEP 연구 그룹이 수행했습니다.
쥐 연구는 두 단계로 진행되었습니다: 1단계 – 3주 (결찰과 박테리아 세척으로 치주염 유발) 및 2단계 – 7일 (치주 치료). 평가된 네 그룹은 음성 대조군, 양성 대조군, 치주 치료를 받은 위약군, 그리고 치주 치료를 받은 QR-01군이었습니다. 주요 지표(탐침 깊이, 잇몸 지수, 탐침 시 출혈, 플라그 지수)는 음성 대조군에 비해 통계적으로 유의한 차이를 보였고, QR-01 치료군에서는 탐침 시 출혈이 감소한 반면 위약군은 증가했습니다.
Nordicus Partners (OTCQB:NORD) la filiale Orocidin a annoncé des résultats précliniques positifs pour son candidat phare contre la parodontite QR-01 le 22 octobre 2025. L'annonce rapporte un second signal d'efficacité sur deux modèles animaux (chien et rat) avec une étude sur rat réalisée par le ETEP Research Group de l'Université Complutense de Madrid.
L'étude sur le rat comportait deux phases : Phase 1 – 3 semaines (induction de la parodontite par ligature et rinçages bacteriens) et Phase 2 – 7 jours (thérapie parodontale). Quatre groupes ont été évalués : contrôle négatif, contrôle positif, placebo avec traitement parodontal, et QR-01 avec traitement parodontal. Les principaux résultats (profondeur de sonde, indice gingival, saignement à la sonde, indice de plaque) ont montré des différences statistiquement significatives par rapport au contrôle négatif, et le saignement à la sonde a diminué dans le groupe traité par QR-01 alors qu'il augmentait dans le groupe placebo.
Nordicus Partners (OTCQB:NORD) Tochtergesellschaft Orocidin gab positive präklinische Ergebnisse für ihren führenden Parodontitis-Kandidaten QR-01 am 22. Oktober 2025 bekannt. Die Ankündigung meldet ein zweites Wirksamkeitssignal über zwei Tiermodelle (Hund und Ratte) mit einer Rattenstudie, durchgeführt von der ETEP Research Group der Universidad Complutense Madrid.
Die Rattenstudie umfasste zwei Phasen: Phase 1 – 3 Wochen (Induktion von Parodontitis durch Ligation + bakterielle Spülungen) und Phase 2 – 7 Tage (parodontale Therapie). Vier Gruppen wurden bewertet: negatives Kontroll, positives Kontroll, Placebo mit parodontaler Behandlung und QR-01 mit parodontaler Behandlung. Wichtige Messgrößen (Tiefenmessung der Sonden, Gingivalindex, Blutung bei der Sondierung, Plaque-Index) zeigten statistisch signifikante Unterschiede gegenüber der negativen Kontrolle, und die Blutung bei der Sondierung nahm in der QR-01-Behandlungsgruppe ab, während sie in der Placebo-Gruppe zunahm.
Nordicus Partners (OTCQB:NORD) أعلنت الشركة التابعة Orocidin عن نتائج واعدة قبل السريرية لمرشحها الرائد في أمراض اللثة QR-01 في 22 أكتوبر 2025. يشير الإعلان إلى إشارة فاعلية ثانية عبر نموذجين حيوانيين (كلب وجرذ) مع دراسة في الجرذان أُجريت من قبل ETEP Research Group في جامعة كومبلوتينسي مدريد.
كانت دراسة الجرذان مقسمة إلى مرحلتين: المرحلة 1 – 3 أسابيع (استحداث مرض اللثة بواسطة الرباط وشطفات بكتيرية) والمرحلة 2 – 7 أيام (علاج لِلتجويف اللثوي). تم تقييم أربع مجموعات: مجموعة ضابطة سلبية، مجموعة ضابطة إيجابية، دواء وهمي مع علاج لِلثة، وQR-01 مع علاج لِلثة. المؤشرات الرئيسية (عمق الخازن، مؤشر اللثة، النزف عند الفحص، مؤشر الترسبات) أظهرت فروقاً ذات دلالة إحصائية مقارنة بالتحكم السلبي، وانخفض النزف عند الفحص في مجموعة QR-01 بينما زاد في مجموعة الدواء الوهمي.
Nordicus Partners (OTCQB:NORD) 的子公司 Orocidin 宣布其治牙周炎领军候选药物 QR-01 的早期实验结果呈积极态势，时间为 2025年10月22日。公告报道在两个动物模型（犬和大鼠）中出现了第二个疗效信号，其中大鼠研究由马德里康普鲁滕塞大学的 ETEP 研究组执行。
大鼠研究分为两个阶段：阶段1 – 3周（通过系带诱导牙周炎并进行细菌冲洗）和阶段2 – 7天（牙周治疗）。共评估四组：阴性对照、阳性对照、接受牙周治疗的安慰剂组，以及接受牙周治疗的 QR-01 组。主要读数（探针探深、牙龈指数、探针出血、牙菌斑指数）与阴性对照相比具有统计学显著差异，QR-01 组的探针出血下降，而安慰剂组有所上升。
- Second positive preclinical result in both dog and rat models
- Study completed with defined protocols: Phase 1 (3 weeks) and Phase 2 (7 days)
- BOP decreased after treatment in the QR-01 group
- PD, GI, BOP, PI showed statistically significant differences versus negative control
- Results are preclinical (animal studies), not human clinical data
- No quantitative efficacy percentages or human timelines provided
BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced the second positive efficacy dog and rat results (in two separate studies) for its lead periodontitis candidate, QR-01, in a preclinical experimental study involving rats with induced periodontitis.
The study was performed by Prof Elena Figuero and Prof Mariano Sanz by the ETEP Research Group at the University Complutense of Madrid, Spain. Professor Figuero and Professor Mariano both acknowledge the value of the study in demonstrating the clinical effect of this compound in improving the clinical outcomes measured in this experimental in vivo investigation, similarly as in the results from the dog study previously performed. “We are both very happy about the data and the outcome of the study” they said.
The rat preclinical in vivo study consisted of two different phases. In Phase 1 (3 weeks), periodontitis was induced using a combination of ligature placement and oral rinses with periodontal pathogenic bacteria. In Phase 2 (7 days), periodontal therapy was performed in the corresponding groups.
These phases led to four experimental groups based on the combination of periodontitis induction and periodontitis treatment, with or without QR-01.
- Negative Control Group: No periodontitis induction and no treatment
- Positive Control Group: Periodontitis induction (ligature placement and oral rinses with bacteria) without periodontal treatment
- Placebo Group: Periodontitis induction (ligature placement and oral rinses with bacteria) with periodontal treatment + placebo gel
- Test Group: Periodontitis induction (ligature placement and rinses with bacteria) with periodontal treatment + QR-01 gel
The results from the rat study demonstrated the following outcome
Probing depth (PD-mm)
- After periodontitis induction, all groups with induced periodontitis exhibited statistically significant differences in PD compared to the negative control group (p < 0.001).
Gingival index (GI)
- After inducing periodontitis, all groups with the condition showed statistically significant differences in GI compared to the negative control group.
Bleeding on probing (BOP)
- After inducing periodontitis, all groups with the condition showed statistically significant differences in BOP compared to the negative control group.
- From a descriptive perspective, after treatment of periodontitis, BOP decreased in the active treatment QR-01 group, whereas an increase was observed in the placebo gel group.
Plaque levels (PI)
- After periodontitis induction, all groups with induced periodontitis showed statistically significant differences in PI compared to the negative control group.
Allan Wehnert, CEO & Founder of Orocidin stated “we are extremely satisfied with the outcome of the study as it confirms the value of QR-01 and shows excellent results. The study was conducted with high professionalism and excellency.”
This is the second pre-clinical animal study demonstrating positive effect in the treatment of periodontitis and shows that the effect of QR-01 is robust and replicable in the treatment of periodontitis and show great prominence for demonstrating clinical effect in periodontitis patients.
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Attachment
FAQ
What did Nordicus (NORD) announce on Oct 22, 2025 about QR-01?
What animal models demonstrated QR-01 efficacy in Nordicus (NORD) studies?
What were the rat study timelines and design for QR-01 reported by Nordicus (NORD)?
How did QR-01 affect bleeding on probing (BOP) in the Oct 22, 2025 announcement?
Does the Oct 22, 2025 Nordicus (NORD) release report human clinical data for QR-01?
